Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of HH-120 Nasal Spray in Healthy Subjects
NCT05753878Phase 1Completed
- Sponsor
- Huahui Health
- Start
- Nov 2022
- Primary completion
- Jan 2023
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of HH-120 in coronavirus disease 2019 (COVID-19) (5 arms), sponsored by Huahui Health. Primary endpoints: The distribution of HH-120 in the nasal cavity, Local drug concentration of nasal and nasopharyngeal swab samples and 1 more. Started Nov 2022; status: completed.
02
Drugs
HH-120
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05753878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05753878.